

Please delete claims 49 and 50 and add new claims 68-76.

68. The method of claim 65 wherein said mammalian PP2C α gene comprises a human PP2C α gene.
69. A method of introducing a vector into cancerous cells including the steps of
 - (a) detecting a type of cancerous cells in the patient wherein a decrease in PP2C α gene activity is detected;
 - (b) preparing a vector specific to the cancerous cells comprising an expression control sequence operatively linked to the nucleic acid sequence of mammalian PP2C α , said vector being capable of targeting said cancerous cells, and
 - (c) introducing said vector into said cancerous cells.
70. The method of claim 69 wherein the mammalian PP2C α gene comprises a human PP2C α gene.
71. The method of claim 69, wherein said introducing of said vector is performed according to a method selected from the group consisting of stable transfection, transient transfection, lipofection, electroporation and infection with recombinant viral vectors.
72. The method according to claim 69 wherein said vector includes at least one targetor moiety.
73. The method according to claim 72 wherein said targetor moiety is a receptor.
74. The method according to claim 72 wherein said targetor moiety is a ligand.
75. The method according to claim 69 wherein PP2C α gene activity is defined by assaying mRNA complementary to PP2C α DNA including polymorphisms thereof in the cells with an assay selected from the group consisting of in situ hybridization, Northern blotting and reverse transcriptase – polymerase chain reaction.